How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors
According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).
Show Me How This Industry Could Explode!
Jinn Wu, insider at Athenex
Jinn Wu Insider Alerts

Get notified the next time Jinn Wu buys or sells Athenex stock. Enter your email address below to get our daily insider buying and selling report.

Jinn Wu Insider Information

Director of Athenex

Jinn Wu is the Founder and President of XenoBiotic Laboratories, Inc. (XBL) in Plainsboro, New Jersey, and XBL- China in Nanjing, China. Both are contract research organizations that provide an extensive array of clinical and preclinical research services to the life sciences, biotechnology and pharmaceutical industries. Jinn earned a PhD in Natural Products and Medicinal Chemistry from the College of Pharmacy, The Ohio State University, and spent 7 years as a research leader at FMC Corporation in Princeton, NJ, and made numerous contributions in new products research and development before starting XBL. He has extensive knowledge and experience in new drug and product R&D. He is an Adjunct Professor at the University of Medicine and Dentistry of New Jersey (UMDNJ at Rutgers) since 2006, was a member of the Advisory Committee for Dean’s Council and is a member of the College of Pharmacy, The Ohio State University (2007-2013). He is also an Adjunct Professor at The Hong Kong Polytechnic University (2015 – present). He holds professional membership of the American Association of Pharmaceutical Scientists (AAPS), the International Society for the Study of Xenobiotics (ISSX), the American Society of Pharmacognosy (ASP) and the American Chemical Society (ACS). He has served as Chief Scientific Officer and Strategic Scientific Advisor at WuXi AppTec, Lab Testing Division. He has also served on the Board of Directors of Ardent Pharmaceuticals and Enhance Biotech, Inc.

Jinn has been very active in public services including many non-profit scientific associations and charitable organizations. Dr. Wu was the recipient of The Jack L. Beal Postbaccalaureate Award (1994), College of Pharmacy, The Ohio State University and the recipient of the Distinguish Alumni Award (2007) from The National Taiwan University. He is also the Keynote Speaker for the Research Day at the College of Pharmacy, The Ohio State University, April 7, 2015.

What is Jinn Wu's net worth?

The estimated net worth of Jinn Wu is at least $790,468.32 as of October 15th, 2018. Dr. Wu owns 311,208 shares of Athenex stock worth more than $790,468 as of October 22nd. This net worth evaluation does not reflect any other assets that Dr. Wu may own. Learn More.

How do I contact Jinn Wu?

The corporate mailing address for Dr. Wu and other Athenex executives is 1001 Main Street Suite 600, Buffalo NY, 14203. Athenex can also be reached via phone at (716) 427-2950 and via email at [email protected]

Has Jinn Wu been buying or selling shares of Athenex?

During the past quarter, Jinn Wu has bought $26,700.00 of Athenex stock. Most recently, on Friday, October 1st, Jinn Wu bought 10,000 shares of Athenex stock. The stock was acquired at an average cost of $2.67 per share, with a total value of $26,700.00.

Who are Athenex's active insiders?

Athenex's insider roster includes Kim Campbell (Director), Johnson Lau (CEO), Jinn Wu (Director), and William Zuo (Insider).

Are insiders buying or selling shares of Athenex?

During the last year, Athenex insiders bought shares 8 times. They purchased a total of 82,000 shares worth mmore than $334,927.50. During the last year, insiders at the sold shares 1 times. They sold a total of 419,931 shares worth mmore than $1,898,088.12. The most recent insider tranaction occured on October, 01st when Jinn Wu Director bought 10,000 shares worth more than $26,700.00. Insiders at Athenex own 14.2 % of the company.

Information on this page was last updated on 10/1/2021.

Jinn Wu Insider Trading History at Athenex

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2021Buy10,000$2.67$26,700.00View SEC Filing Icon  
9/14/2021Buy50,000$3.22$161,000.00View SEC Filing Icon  
10/15/2018Buy12,500$13.47$168,375.00311,208View SEC Filing Icon  
9/6/2018Buy2,500$16.09$40,225.00266,708View SEC Filing Icon  
8/20/2018Buy5,000$17.20$86,000.004,000View SEC Filing Icon  
3/26/2018Buy10,000$14.66$146,600.00259,208View SEC Filing Icon  
2/9/2018Buy10,000$13.64$136,400.00249,208View SEC Filing Icon  
See Full Table

Jinn Wu Buying and Selling Activity at Athenex

This chart shows Jinn Wu's buying and selling at Athenex by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Athenex Company Overview

Athenex logo
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
Read More

Today's Range

Now: $2.54
Low: $2.50
High: $2.60

50 Day Range

MA: $3.26
Low: $2.50
High: $3.89

2 Week Range

Now: $2.54
Low: $2.50
High: $15.00


20,658 shs

Average Volume

959,209 shs

Market Capitalization

$277.65 million

P/E Ratio


Dividend Yield



Small Cap Wonder
Read why this microcap stock might stand out in the market.
Get the info now.